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● Further dose-escalation will define recommended dose for evaluation of clinical activity in 
expansion cohorts
● Study amended to include non-Hodgkin’s lymphoma (NHL) in monotherapy portion
− CDX-1140 has direct killing effect on CD40-expressing NHL cells2
● Future opportunities include combinations with varlilumab (in lymphomas), 
radiation therapy, and/or checkpoint blockade
− Several B cell lymphomas including DLBCL and follicular lymphoma
express CD40 and CD27
− Varlilumab is a potent anti-CD27 agonist
− CDX-1140 synergizes with varlilumab in NHL models8
● Agonist CD40 mAbs can mediate antitumor immunity1
− Enhance tumor antigen presentation by dendritic cells (DCs)
− Activate tumoricidal macrophages
− Direct growth inhibition/killing of CD40-expressing tumor cells
● CDX-1140: fully human IgG2 agonist anti-CD40 mAb2
− Activates DCs and B cells in an FcR-independent manner
− Potent antitumor activity against CD40-expressing cancer 
cells
− Unique and linear dose-dependent in vitro and in vivo 
activity; should allow for significant tumor and tissue 
penetration without dose limiting-toxicities (DLT) from 
systemic CD40 activation
● CDX-301 (rFLT3L): DC growth factor3, 4
− Increases multiple DC subsets in blood and tissues
− May mediate antitumor immunity through promotion of 
CD141+ DCs, tumor antigen uptake and cross presentation 
to CD8+ T cells5
● CD40 ligation and FLT3L are synergistic in murine tumor 
models6, 7
Study Design
● Phase 1 dose-escalation and cohort expansion study 
evaluating safety, PK, PD, and preliminary clinical activity of 
CDX-1140 as monotherapy and in combination with CDX-301
● Patients with advanced solid tumors who have exhausted 
standard-of-care treatment options, with measurable disease 
and documented progression 
CDX-1140 monotherapy 
● Dose escalation from 0.01 to 3.0 mg/kg IV q4w
− 1+5 design for 1st two dose levels, then 3+3 design thereafter
● DLT evaluation period: 28 days after the 1st infusion
CDX-1140 in combination with CDX-301 
● CDX-1140 dose escalation from 0.09 to 3.0 mg/kg IV q4w
− 3+3 design for all cohorts
● CDX-301 (75 µg/kg sc) x 5 days prior to 1st two CDX-1140 
doses
● DLT evaluation period: 35 days after the 1st CDX-1140 infusion 
(i.e., 7 days after the 2nd infusion)
Pharmacokinetic Analysis
Activation of Peripheral Blood Immune Cells 
Dose-Dependent Induction of Pro-Inflammatory 
Cytokines and Chemokines
Monotherapy
(n=13)
Combination
(n=4)
Age, years 
(median, [range])
64.5 (44-81) 60.5 (53-83)
Male 9 (69%) 2 (50%)
ECOG
0 5 (38%) 0
1 8 (62%) 4 (100%)
No. prior treatment 
regimens (mean [range])
4 (1-9) 3 (2-5)
Prior checkpoint inhibitor 7 (54%) 1 (25%)
Prior chemotherapy 12 (92%) 4 (100%)
Toxicity
● 1 DLT (CDX-1140 monotherapy, 0.18 mg/kg): grade 3 
pneumonitis and hypoxia. Patient subsequently died 
due to Enterobacter pneumonia/bacteremia deemed 
unrelated to CDX-1140 
● No other treatment related SAEs or treatment related 
deaths
● All additional treatment-related toxicity grade 1-2: 
nausea, fatigue, anorexia, arthralgia, myalgia, fever, 
chills, generalized muscle weakness, hot flash, 
dizziness
No Significant Drug-related Changes in 
Liver Function Tests or Platelets
Mean (± SD) serum levels of CDX-1140 (monotherapy) following first 90 minute infusion
Preliminary Evidence of Increased Immune Activity with 
Combination of CDX-1140 and CDX-301
Enhanced cytokine production
Baseline Patient Characteristics
ClinicalTrials.gov: NCT03329950
Expected dose-dependent, transient decrease in lymphocytes 
also observed (see flow cytometry)
Monocytes
BACKGROUND INITIAL RESULTS 
Presented at the 33rd Annual Meeting of 
the Society for Immunotherapy of Cancer, 
November 9, 2018/ Poster #403
0.01 mg/kg (n=2)
Pancreatic, CRC
Monotherapy (n=13) Combination (n=4)
0.18 mg/kg (n=7)
Pancreatic, CRC, 
Gastric, RCC (x2), 
HNSCC, Ovarian
0.09 mg/kg (n=3)
HNSCC, Ovarian, 
Cholangiocarcinoma
0.03 mg/kg (n=1)
Bladder
0.09 mg/kg (n=4)
Pancreatic, CRC, 
Mesothelioma, NSCLC
One DLT (pneumonitis & hypoxia)
DLT evaluation complete; dose-
escalation proceeding
Observation for 
DLT ongoing
Dose-Escalation Status
Data shown as n (%) unless otherwise specified.
● CDX-1140 monotherapy to date (at doses ≤ 0.18 mg/kg): 
− Well-tolerated with minimal drug-related toxicity 
− Transient, dose-dependent pharmacodynamic effects 
− Results consistent with CD40-mediated immune cell 
activation and the hypothesis that CDX-1140 may achieve 
dose levels optimal for systemic exposure
● CDX-1140 (at 0.09 mg/kg) in combination with CDX-301:
− No safety concerns to date with initial patients
− Preliminary evidence of enhanced immune activation
CONCLUSIONS AND FUTURE DIRECTIONS
● CDX-1140 is 
quantifiable at 
doses ≥ 0.09 mg/kg
● Exposure appears 
dose proportional
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* Patient with common bile duct obstruction unrelated to CDX-1140.
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*CDX-301 is administered for patients in the combination portion only
